Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Moik, F; Riedl, JM; Ay, C.
VTE with Amivantamab plus Chemotherapy in NSCLC.
N Engl J Med. 2024; 390(6): 578-579. Doi: 10.1056/NEJMc2314937
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Moik Florian
Co-authors Med Uni Graz: Riedl Jakob
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: To the Editor: In their article on the PAPILLON trial, Zhou et al. (Nov. 30 issue)(1) describe the promising efficacy of amivantamab plus chemotherapy in patients with untreated advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions. However, highly relevant questions remain open concerning the cardiovascular safety of amivantamab-based therapies, an issue that has been raised in previous studies.(2-4) In particular, a high risk of venous thromboembolism (VTE) was reported in several trials investigating amivantamab in NSCLC as compared with control therapies, with the incidence of VTE ranging from 10% with amivantamab to 21 to . . .
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Venous Thromboembolism - drug therapy; Carcinoma, Non-Small-Cell Lung - complications, drug therapy; Lung Neoplasms - complications, drug therapy; ErbB Receptors - administration & dosage; Antibodies, Bispecific - administration & dosage